Sandoz Fights Amgen Enbrel Patent

Law360, New York (June 26, 2013, 5:24 PM EDT) -- Amgen Inc. and Hoffman-La Roche Inc. were struck with a California federal lawsuit Tuesday from Sandoz Inc. that says a generic form of arthritis drug Enbrel is not infringing two patents and a delay in the patents' issuance renders them invalid.

The disputed patents, for formulations of the pharmaceutical compound etanercept, are not valid because they were improperly issued more than 15 years after Hoffman-LaRoche first filed, the complaint says. By allowing so much time to elapse before approval, the U.S. Patent and Trademark Office damaged...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.